Global HER-2 Positive Breast Cancer Market 2015-2019

1
Global HER-2 Positive Breast Cancer Market
2015-2019
2
DESCRIPTION
About HER-2 Positive Breast Cancer Breast cancer
is characterized by uncontrolled growth of
cancerous cells in the breast. It occurs in both
males and females, however, the incidence of
breast cancer in males is rare. Histologically,
breast cancer can be classified into ductal
carcinoma, lobular carcinoma, nipple cancer, and
other undifferentiated carcinoma. Breast cancer
is the second most common form of cancer in
women. HER-2 is a protein that affects the growth
of malignant cells and is usually found on the
surface of normal breast cells. Sometimes, a
large number of HER-2 receptors are found on the
surface of breast cancer cells. These HER-2
receptors are responsible for stimulating the
growth and division of malignant cancerous cells.
This condition is therefore known as HER-2
positive breast cancer. HER-2 positive breast
cancers have a tendency to spread and metastasize
more rapidly than HER-2 negative breast cancers.
HER-2 positive breast cancer is more prevalent in
females than males. In 2012, GLOBOCAN reported
that breast cancer accounted for 11.9 percent of
the total number of cancer cases and led to
522,000 deaths worldwide. HER-2 positive breast
cancer accounts for almost 25 percent of all
types of breast cancer.   The Global HER-2
Positive Breast Cancer market to grow at a CAGR
of 9.90 percent over the period 2014-2019.   Read
more details at http//www.bigmarketresearch.com/
global-her-2-positive-breast-cancer-2015-2019-mark
et  
3
REPORT OVERVIEW
Covered in this Report This report covers the
present scenario and the growth prospects of the
Global HER-2 Positive Breast Cancer Market for
the period 2015-2019. To calculate the market
size, the report considers revenue generated
through the sales of targeted therapeutic agents,
chemotherapeutic agents, and hormonal therapies
that are used in the management of HER-2 positive
breast cancer patients.   The report also
presents the vendor landscape and a corresponding
detailed analysis of the top vendors in the
Global HER-2 Positive Breast Cancer market. In
addition, it discusses the major drivers that
influence the growth of the market. It also
outlines the challenges faced by the vendors and
the market at large, as well as the key trends
that are emerging in the market.   Global HER-2
Positive Breast Cancer Market 2015-2019, has been
prepared based on an in-depth market analysis
with inputs from industry experts. The report
covers the Americas, and the EMEA and APAC
regions it also covers the Global HER-2 Positive
Breast Cancer market landscape and its growth
prospects over the coming years. The report also
includes a discussion of the key vendors
operating in this market.
4
KEY BENEFITS
Key Regions Americas APAC EMEA
  Key Vendors Celgene F. Hoffmann-La Roche
GlaxoSmithKline Novartis Sanofi
5
KEY AUDIENCES
Other Prominent Vendors Actavis Array
BioPharma Biocad Biocon Boehringer
Ingelheim Bristol-Myers Squibb Celltrion
Chugai Pharmaceutical DARA BioSciences
EddingPharm Eisai Galena Biopharma
Halozyme Therapeutics Hospira Mylan
Oncothyreon Pfizer ProStrakan Puma
Biotechnology Sun Pharmaceutical Industries
6
KEY AUDIENCES
Market Driver Increase in Population of Breast
Cancer Patients For a full, detailed list, view
our report   Market Challenge Poor Diagnosis
and Screening For a full, detailed list, view
our report   Market Trend Increase in
Awareness For a full, detailed list, view our
report
7
KEY AUDIENCES
Key Questions Answered in this Report What will
the market size be in 2019 and what will the
growth rate be? What are the key market
trends? What is driving this market? What are
the challenges to market growth? Who are the
key vendors in this market space? What are the
market opportunities and threats faced by the key
vendors? What are the strengths and weaknesses
of the key vendors?   Enquire about report
http//www.bigmarketresearch.com/report-enquiry/18
3658  
8
Get Full Information At http//www.bigmarketrese
arch.com/global-her-2-positive-breast-cancer-2015-
2019-market